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The risk of Alzheimer’s disease (AD) is highly dependent on
apolipoprotein-E (apoE) genotype. The reasons for apoE iso-
form-selective risk are uncertain; however, both the amounts
and structure of human apoE isoforms have been hypothe-
sized to lead to amyloidosis increasing the risk for AD. To
address the hypothesis that amounts of apoE isoforms are
different in the human CNS, we developed a novel isoform-
specific method to accurately quantify apoE isoforms in clin-
ically relevant samples. The method utilizes an antibody-free
enrichment step and isotope-labeled physiologically relevant
lipoprotein particle standards produced by immortalized
astrocytes. We applied this method to a cohort of well char-
acterized clinical samples and observed the following find-
ings. The apoE isoform amounts are not different in cerebro-
spinal fluid (CSF) from young normal controls, suggesting
that the amount of apoE isoforms is not the reason for risk
of amyloidosis prior to the onset of advanced age. We did,
however, observe an age-related increase in both apoE iso-
forms. In contrast to normal aging, the presence of amyloid
increased apoE3, whereas apoE4 was unchanged or de-
creased. Importantly, for heterozygotes, the apoE4/apoE3
isoform ratio was increased in the CNS, although the reverse
was true in the periphery. Finally, CSF apoE levels, but not
plasma apoE levels, correlated with CSF -amyloid levels.
Collectively, these findings support the hypothesis that CNS
and peripheral apoE are separate pools and differentially reg-
ulated. Furthermore, these results suggest that apoE mecha-
nisms for the risk of amyloidosis and AD are related to an
interaction between apoE, aging, and the amount of amyloid
burden.
The largest risk factors for developing late-onset Alzheimer’s
disease (AD)2 are advanced age and apolipoprotein-E (APOE)
genotype. ApoE is a 34-kDa lipoprotein with 299 amino acid
residues expressed primarily by astrocytes in the central nerv-
ous system (CNS) and by hepatocytes and macrophages in the
periphery (CNS) (1). In humans, theAPOE gene is polymorphic
with three high frequency alleles, APOE-2, APOE-3, and
APOE-4. The expressed allelic isoforms differ by single cys-
tine-arginine replacements as follows: apoE2 (R112C and
R158C), apoE3 (R112C), and apoE4 (2). These alleles are asso-
ciated with differential AD risk, where APOE-2 is protective
and APOE-4 increases risk in a dose-dependent manner (3-
and 12-fold for heterozygotes and homozygotes, respectively)
compared with the most prevalent APOE-3 allele (78% in the
Caucasian American population (3, 4)). Taken together, varia-
tions in the APOE gene may account for at least 50% of the
population-attributable risk in late-onset AD (5).
The role of apoE in AD pathogenesis has been attributed to
numerousmechanisms based on both in vitro and in vivo obser-
vations (6). Briefly, apoE is a proteinaceous component of both
plaques and tangles (7) that binds to and effects the deposition
of -amyloid (A) in an isoform-dependent manner (8–10).
ApoE4 exacerbates oligomerization (11), cortical plaque depo-
sition (12), and intra-neuronal concentrations of A (13–15).
Furthermore, apoE isoform expression also impacts the clear-
ance of A (16), with the observed effects speculated to be de-
pendent on each respective isoform’s lipidation state and/or
affinity for cognate receptors (17–19). Finally, there is also evi-
dence of direct cleavage of the apoE4 isoform into toxic frag-
ments within neurons (20) that are implicated in aberrant Tau
phosphorylation (21). Taken together, it is clear that apoE iso-
form expression plays a central role in the modulation of AD
pathology and that a better understanding of apoE pathophys-
iology is essential for apoE-directed drug development.* This work was supported by National Institutes of Health Grants
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To this end, multiple groups have attempted to establish
whether isoform-dependent differences in the amount of apoE
exist in the CNS. Astrocyte-derived apoE is a separate pool
from liver-derived apoE in the periphery (22) and is found at
concentrations of5–10g/ml in CSF and 50g/ml in plasma
(23). Peripheral apoE measured in plasma has previously been
shown to decrease with APOE-4 carrier status (23–26). In the
CNS, ELISA-basedmethods for estimating the relative or abso-
lute amounts of apoE allelic isoforms have yielded conflicting
results, possibly due to isoform-specific antibody preference
and inherent variability of the assay. For example, in human
CSF, conflicting reports of increased apoE4 mole fraction (27),
decreased apoE4 mole fraction (28), and an equal apoE4 mole
fraction have been reported (29).
These inconsistent results indicate a need for validated
simultaneous measures of apoE isoforms and robust quantita-
tive methods with better precision and unbiased isoform spec-
ificity. One candidate technique is targeted mass spectrometry
used in conjunction with stable isotope-labeled analytical stan-
dards (30). The decisive analytical advantages of this approach
over the classically deployed immunoassays have led to its
widespread application in clinical research laboratories. Previ-
ous efforts to use targeted proteomics to characterize allelic
isoforms of apoE were based on isoform-specific tryptic pep-
tides and typically relied on either isotope-labeled synthetic
peptides (31) or recombinant proteins (32) as analytical stan-
dards. Studies that utilize synthetic peptide standards are
unlikely to yield true absolute measurements due to their
inability to control for variation introduced during the enrich-
ment and proteolytic digestion steps of sample processing
(both of which may introduce isoform-specific biases). Simi-
larly,methods utilizing purified recombinant protein standards
may also be insufficient. The behavior of lipidated apoE during
purification differs distinctly from the purified non-lipidated
protein (33). In an effort to address the shortcomings of these
methods, we developed a targeted proteomics method that is
both antibody-independent and based on a set of physiologi-
cally relevant human apoE3 and apoE4 stable isotope-labeled
lipoprotein standards produced in mouse immortalized astro-
cytes. After initial assay validation, we applied this novel tech-
nique to a set of well characterized clinical samples in an effort
to compare apoE isoform amounts without assay bias. We
selected a wide range of samples from plasma, CSF, and brain
with a range of ages and amount of amyloidosis to better under-
stand the relationship between apoE isoform expression in the
CNS and periphery within the context of increasing age and
amyloid burden.
Results
Accuracy of Total and Isoform-specific ApoE Measures—
After generation of the stable isotope-labeled apoE3 and apoE4
standards in independent cultures of immortalized astrocytes,
we performed cross-titration experiments to ensure that the
final internal standard mix contained equal amounts of apoE3
and apoE4.We determined that an apoE3/apoE4 ratio of 2.54:1
of labeled astrocyte-derived media stocks provided an equimo-
lar mix of these isoforms, and we used this ratio to make the
internal standard mix for all subsequent analyses (see Fig. 1C.)
To validate the accuracy of our stable isotope absolute quan-
titation using lipoprotein particle internal standards, we exam-
ined the consistency of our results across isoform-specific and
four common peptides (reflecting total apoE). The common
peptides in CSF were very strongly correlated to one another
and to the isoform-specific peptide total (E3 inAPOE-3/3, E4
in APOE-4/4, and sum of E3 and E4 in APOE-3/4 partici-
pants), with coefficients of correlation within participants of
0.95 or greater (p  0.0001) and a slope of 1.025 for the com-
mon peptide average versus the isoform-specific sum (Table 1).
For brain samples with quantitative measures of apoE isoforms
(excluding APOE-2 carriers), isoform and common measures
of total apoE were strongly correlated (R  0.93; p  0.0001)
with a slope of 1.14. Similar results are obtained when the
results are analyzed by apoE genotype (Fig. 1D).
Calibration curves for each peptide were constructed (data
not shown), and all measurements reported fell within the lin-
ear portions of these curves. The lowest point on each calibra-
tion curve is reported as each peptide’s lower limit (Table 2).
Measurement of plasma apoE by MS and ELISA exhibited a
very strong correlation (Pearson’s R  0.80, p  0.0001 for
common peptides versus ELISA and R  0.86, p  0.0001 for
isoform-specific peptides versus ELISA). MS and ELISA mea-
sures also demonstrated similar trends of decreasing total apoE
with increasing apoE4 copy number, as has been widely
reported previously (Fig. 2).
Absolute Amount of ApoE3 andApoE4 Isoforms inCSF, Fron-
tal Cortex, and Plasma—To determine whether the differential
risk for AD byAPOE genotype could be due to the apoE protein
amount in the CNS, we examined apoE3 and apoE4 isoform
amounts in CSF and brain from heterozygote carriers.
Higher apoE4 compared with apoE3 was observed in CSF
and brain of nearly all APOE-3/4 individuals examined,
whereas plasma from heterozygotes showed the opposite rela-
tionship (Fig. 3A). Student’s t tests showed a higher mole frac-
tion of apoE4 in heterozygote CSF, which reached statistical
significance in this cohort, 53.0% apoE4 (t(6) 2.5, p 0.05) in
YNCs, and 55.6% apoE4 (t(34) 17.8, p 0.0001) in the older
cohort. Similarly, 56% apoE4 was observed in frontal cortex
samples fromheterozygotes t(16) 6.8, p 0.0001. For plasma
within the same CSF subjects, the ratio reversed such that
70.7% of apoE was apoE3, t(17) 16.6, p 0.0001.
CSF and plasma apoE4/apoE3 isoform ratios were negatively
correlated between paired plasma and CSF samples. A signifi-
cant negative correlation (Pearson’s R  0.47, R2  0.022, p
(two-tailed)  0.047) was observed between apoE4/apoE3
ratios from APOE-3/4 participants where both CSF and
plasmaweremeasured (Fig. 3B). In contrast, no significant cor-
relations were found for total apoE, apoE3, and apoE4 amounts
between plasma and CSF. These findings suggest opposite
metabolism of apoE4 and apoE3 between the CNS and
periphery.
Age-associated Increase in apoE—We assessed apoE isoform
amounts in CSF across the adult life span. Comparing the
means between age groups with age 60 as the cutoff, increasing
age was correlated with a 39% increase in total apoE as mea-
sured by the four common peptides, 34% increase in gene dose-
normalized apoE3 amount and 50% increase apoE4 amount.
ApoE Isoforms in Human CSF, Brain, and Plasma
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ANOVAof gene dose-normalized amounts of total, apoE3, and
apoE4 by age group was highly significant (F(5,240) 6.7, p
0.0001). Each comparison between age groups was individually
significant within the analysis: total apoE p 0.006, apoE3 p
0.04, and apoE4 p  0.02 (adjusted p values for multiple com-
parisons reported). Furthermore, linear regression of gene
dose-normalized total apoE, apoE3, and apoE4 amounts
revealed significant increases with age as follows: total (com-
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mon) apoE 0.0058age 0.47, R2 0.11, p 0.0006; apoE3
amount  0.0048age  0.51, R2  0.87, p  0.0035; apoE4
amount  0.0070age  0.44, R2  0.14, p  0.0087, approxi-
mating an 8% increase in apoE amount per decade of life (Fig. 4).
Similar linear trends were observed when data were restricted
to -amyloid-negative participants, although the trend for
apoE4 did not reach significance because the majority of apoE4
carriers are-amyloid-positive (37 versus 7-amyloid-negative
in the older cohort and 9 in the YNC cohort).
To confirm the findings in YNC samples, whichwere initially
processed separately fromolder CSF, a subset of YNC and older
subject samples was reprocessed and analyzed simultaneously,
and the results confirmed the effects and their magnitude.
-Amyloidosis and Genotype Effects on ApoE Amount—To
determine the effect of amyloidosis on apoE variant protein
levels, gene dose-normalized variant amounts and total apoE
were compared in those with and without amyloidosis. The
strongest effect was observed in the CSF from -amyloid-pos-
itive older participants. A decreasing amount of apoE was
observed with APOE-4 carrier status (APOE-3/3  APOE-
3/4  APOE-4/4) for total apoE (average common pep-
tides; F(2,40)  1.4, p  0.0019; Fig. 5C, bottom panel), with
mean(S.D.) apoE amounts of 1.06(0.20)  0.90(0.26) 
0.53(0.12) normalized units. Similar independent decreases
were observed for apoE3 (APOE-3/3  APOE-3/4;
mean(S.D.)  0.52(0.10)  0.40(0.11) normalized units; p 
0.0025) and apoE4 variants (APOE-3/4  APOE-4/4;
mean(S.D.)  0.50(0.13)  0.29(0.06); p  0.0050; Fig. 5C, top
and middle panels). A decrease in brain apoE3 in APOE-
4 carriers was observed (APOE-3/3  APOE-3/4;
mean(S.D.)  0.66(0.18)  0.52(0.21); p  0.02), but the same
trend toward a decrease in total apoE in brain did not
reach statistical significance (APOE-3/3  APOE-3/4;
mean(S.D.) 1.59(0.49) 1.31(0.52); p 0.07; Fig. 5D). In the
YNCcohort, older-amyloid-negative cohort and plasma sam-
ples, neither variant nor total CSF apoE amounts (measured by
average of the common peptides), differed by genotype when
compared across groups (Fig. 5, A, B, D, and E). However, a
trend toward a decrease with APOE-4 carrier status was con-
firmed in plasmawhen total apoE represented by the sumof the
variant-specific peptide measures was performed (APOE-3/
3  APOE-3/4  APOE-4/4; mean(S.D.)  7.70(2.64) 
6.82(2.35)  3.91(1.64); F(2,34)  3.9, p  0.03), although the
effect failed to reach significance when the average common
peptides were compared across genotypes (p 0.21).
Of interest, frontal cortex from APOE-3/3 and APOE-
3/4 participants contained a 50% higher concentration of
apoE than CSF from the older cohort (Fig. 5, B–D). Plasma
apoE concentration was10-fold higher than CSF (Fig. 5, B,
C, and E).
To assess the effect of -amyloidosis on total apoE and on
apoE3 and apoE4 variants, a comparison was made by -amy-
loid status (Fig. 6). APOE-3/3 participants, in particular,
exhibited significant increases in total apoE and apoE3 amounts
such that YNC  -amyloid  -amyloid. Within APOE-
3/3 individuals, ANOVA demonstrated a significant differ-
ence in CSF apoE3 amount (F(2,51) 4.3, p 0.019), as well as
total apoE (F(2,51)  5.9, p  0.0049). Post hoc comparisons
showed that only the difference between YNC and amyloid
groups reached statistical significance (p  0.014 for apoE3
amount, p 0.0034 for total apoE). A trend toward an increase
in apoE3 amount with amyloidosis in the older APOE-3/3
cohort did not reach significance (p  0.20 for apoE3 amount
and p 0.20 for total apoE). Within APOE-3/4 individuals, a
similar result was seen for apoE4 amount (F(2,39)  4.2, p 
0.023), with post hoc significance between YNC and amyloid
groups (p  0.021) and a trend for an increase between YNCs
and amyloid (p  0.066). No difference was observed in
apoE4 amount with amyloidosis in the older APOE-3/4
cohort (p 0.99 for apoE3 amount, p 0.99 for apoE4 amount,
and p  0.99 for total apoE). Within APOE-4/4 individuals,
no differences were observed in apoE4 or total amounts
between YNC and -amyloid groups.
FIGURE 1. Demonstration of molar equivalence of apoE3 and apoE4 in internal standard (heavy Arg media) and external standard (CSF titration
curve). A, lipoprotein particle standard production. Immortalized murine astrocytes expressing transgenic human APOE-3 or APOE-4 were incubated in
stable isotope labeling media supplemented with light arginine (unlabeled) or heavy L-[U-13C6,
15N4]arginine (labeled). Culture media were collected with no
label (E3 and E4) or at very high (95%) label incorporation (E3* and E4*). B, lipoprotein particle cross-titration. To estimate the concentration of E3* media
relative to E4* media, inverted dilution curves of E3*(decreasing) and E4*(increasing) media were added to a consistent volume of unlabeled E3/E4 media.
Selected peptides were detected in a linear fashion by LC/SRM across the volumes used. C, lipoprotein particle molar equilibration. Although the titration
proportions were held constant as shown in B, the actual volume of E4* media was adjusted to identify the E4*/E3* ratio where common peptides were
detected equally along the cross-titration curve. At ratios of 1.5 (C, top panel) and 4 (C,middle panel) E4*/E3*media by volume, common peptides had positive
andnegative slopes, respectively, demonstrating differentmolar ratios. Based on these results, apoEmolar equivalencewas determined to be 2.54 timesmore
concentrated in E3* than in E4*media (C, bottompanel). A dilution curve using 2.54:1 ratiowas tested, and fit lineswere found to have an average slope of 0.11
across four common peptides, indicating that the two standards were in molar equivalence. This equilibrated media ratio (note horizontal apoE amounts in
mixing titration experiment) was used to incorporate isoform-equilibrated E3* and E4* internal standards in all samples. Similar cross-titration experiments
were carried out using human APOE-3 and APOE-4 homozygote CSF (unlabeled, usingmolar equivalent E3*/E4* internal standards) to equilibrate standard
curves used in absolute quantitation of isoforms (data not shown). D, correlation of total and isoform-specific apoE measures. Independent measures of CSF
apoE common peptides (averaged for four peptidesmonitored) were consistent with the sum of isoform-specific peptides, producing a slope close to 1 (m
1.025) by linear regression and a significant correlation (R2 0.976, p 0.0001). For brain samples from participants excluding APOE-2 carriers (isoform not
monitored), the isoformand total apoEmeasureswere slightly less precisely correlated (R20.859, standard error0.195,p0.0001,with a slopeof 1.14) but
still approximated equivalentmeasures. Similarly, the correlationwas also significant for plasma samples (R2 0.898, standard error 0.805, p 0.0001, with
a slope of 0.902).
TABLE 1
Correlation of total apoE by common peptide and total apoE by
summed isoform-specific peptide measures in human CSF
When plotted against the isoform-specific quantitation of total apoE in CSF sam-
ples, four common peptides demonstrated a high correlation within participants,
with slopes near 1 and R2 exceeding 0.93.
Peptide
(vs. isoform sum) Slope R2
Standard
error
Significance,
p value
AATVGSLAGQPLQER 1.024 0.933 0.078 0.0001
LAVYQAGAR 1.001 0.962 0.057 0.0001
LGPLVEQGR 1.045 0.965 0.057 0.0001
WELALGR 1.015 0.960 0.059 0.0001
Common-average 1.025 0.976 0.045 0.0001
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Neuropathology Measures and Brain ApoE—To assess
potential effects of mild Alzheimer’s disease neuropathologic
change (ADNC) in cognitively normal brain donors, particu-
larly A and Tau accumulation, comparisons were made
between pathology measures and CNS apoE protein amounts.
For brain samples, pathologymeasures in adjacent tissue (fron-
tal neocortex) by genotype are reported in Table 3. ANOVA of
pathology measures by apoE genotype demonstrated no signif-
icant relationships except for area fraction of-amyloid immu-
nohistochemistry (10D5 antibody); F(3,42)  3.8, p  0.017.
Post hoc Tukey’s analysis showed an increase in area fraction in
APOE-3/4 compared with APOE-3/3 participants, p 
0.041. No correlational relationship was observed between
apoE amounts (gene dose-normalized isoform-specific or total
as the average of common peptides) and pathology, including
A area fraction and area fraction of phosphorylated Tau
(PHF-1 antibody), nor with global pathology as assessed by
Braak staging of neurofibrillary tangles (34), CERAD staging of
neuritic plaques (35), or Thal A staging (36). A positive corre-
lation between apoE amounts and luminance of glial fibrillar
active protein (GFAP), a marker of astrocytosis, was observed
(total (common) apoE 0.018GFAP luminance, 1.2,R2 0.14,
p 0.011).
For bothCSF and plasma samples, individualmeasures of A
pathology amounts, namely PiB score and CSF A 42:40 ratio,
were not found to linearly correlate with apoE amounts. How-
ever, correlations between CSF (but not plasma) apoE amounts
and CSF A40 and A42 amounts were robust (Fig. 7). For
A40 amount andCSF apoE3 isoform amount, the correlations
were highly similar between -amyloid-positive (Pearson’s R
0.77, p  0.0001) and -amyloid-negative participants (R 
0.78, p  0.0001). This was also true for A40 and apoE4
(-amyloid-positive,R 0.84, p 0.0001;-amyloid-negative,
R  0.83, p  0.05) and total apoE amounts (-amyloid-posi-
tive, R  0.81, p  0.0001; -amyloid-negative, R  0.79, p 
0.0001). For A42 amount and apoE amount, the trends were
less similar between -amyloid status groups but still demon-
strated significant correlations (apoE3 for -amyloid-positive,
TABLE 2
SRM data collection parameters
LLOQ’s are reported as the mean (standard deviation) of the peak area ratio from the lowest non-zero point of each peptide’s dilution curve of apoE3/apoE4 molar-
equilibrated CSF plus E3*/E4* media lipoprotein internal standard (across three separate days of analysis).
Variant Peptide Precursor ionm/z Product ionm/z Collision energy Peak area ratio LLOQ
Common WELALGR 422.737 345.224 18 1.09 (0.05)
416.261
529.345
658.388
WELALGR 427.741 355.232 18
(13C6,15N4-R) 426.269
539.353
668.396
E3/E4 LAVYQAGAR 474.767 665.336 19 1.07 (0.10)
764.404
835.442
LAVYQAGAR 479.771 675.344 20
(13C6,15N4-R) 774.413
845.450
Common LGPLVEQGR 484.780 588.309 20 1.12 (0.08)
701.394
798.446
855.468
LGPLVEQGR 489.784 598.318 20
(13C6,15N4-R) 711.402
808.455
865.476
E4 LGADMEDVR 503.237 649.297 20 1.09 (0.06)
764.324
835.361
892.382
LGADMEDVR 508.241 659.305 21
(13C6,15N4-R) 774.332
845.369
902.391
E2/E3 LGADMEDVcGR 611.763 735.309 24 1.004 (0.10)
866.349
981.376
1009.434
LGADMEDVcGR 616.767 745.317 24
(13C6,15N4-R) 876.357
991.384
1119.443
Common AATVGSLAGQPLQER 749.405 642.356 29 0.70 (0.04)
827.437
898.474
1155.611
AATVGSLAGQPLQER 754.409 652.365 29
(13C6,15N4-R) 837.445
908.482
1165.619
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FIGURE 3. ApoE4/apoE3 ratio and inverse relationship between blood apoE and CNS (CSF and brain) apoE. A, isoform ratios. Student’s t tests showed a
higher ratio of apoE4/apoE3 in heterozygote CSF, which reached statistical significance in this cohor:1.14 (t(6) 2.5, p 0.05) in YNCs and 1.26 (t(34) 17.8,
p 0.0001) in the older cohort. Similarly, a ratio of apoE4/apoE3 of 1.29 was observed in brain (t(16) 6.8, p 0.0001). For plasma from a subset of the same
older CSFparticipants, a ratio of1 indicates an inverse relationshipwhere apoE4/apoE3 0.42 (t(17) 16.6,p 0.0001). B, inverse peripheral andCNS ratios.
In plasma and CSF from heterozygote participants with both CSF and plasma analyzed, the apoE4/apoE3 ratios are inversely correlated; slope  0.66,
Pearson’s R0.47, R2 0.022, p (two-tailed) 0.048.
FIGURE 2. Method comparison of apoE quantitation, ELISA versus MS (average common and isoform sum). A, correlation of results. Total apoE from
duplicate plasma samples including apoE3 and apoE4 carriers (n 15 APOE-3/3, 18 APOE-3/4, and 4 APOE-4/4 participants) were analyzed by ELISA and
MS. Whether apoEMSwas calculated by the common peptides or isoform-specific peptides, a very strong correlation with ELISA was observed (R 0.80, p
0.0001 for average common MS versus ELISA, R  0.86, p  0.0001 for isoform sum MS versus ELISA). B–D, decreasing apoE with increasing APOE-4 copy
number. ELISA analysis demonstrated a decrease in apoE amount with each additional APOE-4 allele, with each between-group sub-analysis reaching
statistical significance: APOE-3/3 versus APOE-4/4 p  0.0001, APOE-3/3 versus APOE-3/4 p  0.005, APOE-3/4 versus APOE-4/4 p  0.05 (B). In
contrast, themass spectrometry method did not show differences between APOE-3/3 versus APOE-3/4 in plasma and did not reach statistical significance
between genotypes with MS measures for averaged common peptides (D); however, differences between APOE-3/3 and APOE-4/4 genotypes were
significant, p 0.05, when the comparisonwas based on isoform sum (C). In this figure and subsequent figures, “apoE/labeled apoE ISTD” as an axis label refers
to the ratio of the endogenous analyte unlabeled apoE to the labeled apoE internal standard as measured by ion intensity of the area under the curve for the
chromatographic peak, divided by starting volume of analyte (l), and normalized to the standard curve.
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R  0.61, p  0.0001; apoE3 for -amyloid-negative partici-
pants, R 0.67, p 0.0001; apoE4 for -amyloid-positive, R
0.69, p  0.0001; total apoE for -amyloid-positive, R  0.64,
p 0.0001; total apoE for-amyloid-negative participants,R
0.65, p  0.0001) with the exception of apoE4 for -amyloid-
negative participants (p 0.16).
Discussion
We developed and utilized an apoE isoform-specific method
that is antibody-free to more accurately quantify the amounts
of apoE3 and apoE4 isoforms in CSF, brain, and plasma. The
novel aspect of this method is its use of physiologically relevant
stable isotope-labeled apoE lipoprotein particle standards. All
standards (apoE3 and apoE4, stable isotope-labeled and -unla-
beled) were produced in immortalized astrocytes and presum-
ably mimic each isoform’s native conformation in vivo. This
approach enables both the standards and analytes to be sub-
jected to the same manipulation (protein pulldown, digestion,
alkylation, washes, etc.) prior to LC-MS analysis, which cor-
rects for any isoform-specific bias that might be introduced
during sample preparation. Furthermore, we employed an
antibody-free affinity purification step that ensures all apoE
detected (standards and analytes) consists of soluble lipopro-
tein particles with similar physiochemical properties, including
the mass balance of apoE, cholesterol, and phospholipid as well
as a lipoprotein particle size comparable with high density lipo-
protein (33, 37). One notable difference is the lack of a choles-
terol-ester core in the medium-derived apoE lipoprotein. This
is consistent with the astrocyte-derived lipidated species that
constitutes the major component of CNS apoE but differs from
hepatocyte-derived apoE lipoprotein in the periphery.
As stated previously, ELISA-based methods for the charac-
terization of apoE in the human CNS have yielded conflicting
results. Although generally robust, immunoassays carry a not-
insignificant risk of interferences and biases that could poten-
tially introduce confounding factors to a study. The potential
interferences include the high-dose hook effect, specificity
shortcomings, autoantibodies, and anti-reagent antibodies
(38). Furthermore, ELISA-based assays lack the ability to mea-
sure isoforms independently, detect truncations or fragments,
and identify post-translational modifications. Finally, because
the accuracy of an ELISA is entirely predicated by the standard
with which it is calibrated, these assays lack the necessary con-
cordance across platforms, which ultimately hinders compari-
sons between studies. Because of these and other limitations,
LC-MS methodologies have emerged as a detection method
capable of alleviating many of these inherent shortcomings.
This work represents an extension of the previous development
of LC-MS methods (31, 32) and directly addresses a potential
source of bias (physiochemical differences between standard
and analyte) in these assays.
We applied our antibody-free and isoform-specific LC-MS
method to CSF and plasma samples from a cohort of APO-3/
3, APO-3/4, andAPO-4/4 study participants that spanned
a spectrum of both age and amyloid burden. In addition, we
applied themethod to 41well characterized post-mortembrain
samples (as assessed by relevant biomarker measures). A few
caveats of this study include the relatively low number of
APOE-4/4 homozygote participants and the exclusion of
APOE-2 carriers entirely. Both of these caveats are a reflection
of the population prevalence of these apoE genotypes and their
low frequency in the studied cohort, precluding meaningful
interpretation of results. APOE-2 carriers were left out
because of the very low prevalence in the population (7%),
and power analyses at the design phase of the study indicated
very low probability of meaningful comparisons. Thus, we did
not develop standards for apoE2 or measure apoE2 alleles. Our
primary aims of the grant were specific for the apoE3 versus
apoE4 comparison. Future studies may focus on this, but many
hundreds of samples will be needed for the comparison. Simi-
larly, another caveat to the reported analysis is that all APOE-
4/4 participants in the older cohort are universally -amy-
loid-positive. Additionally, our analyses of post-mortem brain
tissues lacked APOE-4/4 participants due the exclusion of
participants with existing AD neuropathology. Although both
of these limitations are to be expected based on the well estab-
lished amyloid and AD risk for APOE-4/4 individuals in this
age range (40), they prevent a fully independent assessment of
age and-amyloidosis effects on apoE4 amount in homozygous
carriers.
In contrast to previous studies (27, 41), this study observed
no significant difference in apoE isoform expression in the CSF
from the cohort of YNC. This important finding suggests that
an isoform imbalance prior to the onset of advanced age is
unlikely the reason for the elevated risk that APOE-4 carriers
have for amyloidosis. We did observe, however, an age-related
increase in apoE across all isoforms. Previous studies of this
FIGURE 4. ApoE increases with age. A significant positive correlation was
observed between aging and gene dose-normalized apoE3 (R2 0.092, p
0.005) andapoE4 isoforms (R20.142,p0.01) aswell as total apoEamounts
in CSF (R2 0.117, p 0.0005). The effect was still observed when data were
restricted to -amyloid-negative and YNC participants (solid markers) in
apoE3 (R2  0.124, p  0.01) and total apoE (R2  0.153, p  0.005), with a
trend toward increase in apoE4 amount (R2 0.230, p 0.060). Biomarker-
validated amyloid status was not available for YNC cases.
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effect have yielded conflicting results. One study noted an age-
dependent decline inAPOE levels in the control population but
an increase in the AD participants (42), although other studies
observed an age-dependent increase in APOE3 across all par-
ticipants (43, 44). This work is in agreement with the latter and
nicely extends other previous work that noted an age-depen-
dent up-regulation of cholesterol trafficking genes that coin-
cidedwith the onset of cognitive impairment (44, 45). Thenota-
ble exception to this trend in this study is in APOE-4/4
participants, where apoE expression does not appear to
increase as a function of age when combined with -amyloido-
sis. This relationship should be further tested by evaluating
both younger APOE-4/4 individuals and older amyloid-neg-
ative APOE-4/4 individuals. However, as mentioned above,
the rarity of the latter group would make finding a suitable
cohort for these analyses a significant challenge. All things con-
sidered, if increasingCNS apoE amount is a protective response
to age and pathology, then the lack of response from APOE-4
could potentially be a reason for the increased risk inAD.Alter-
natively, APOE-4 may also selectively deposit in the CNS into
amyloid plaques.
Also observed was an apoE isoform-dependent interaction
with -amyloidosis in the human CNS. In APOE-3/3 partic-
ipants, apoE increases with age and further increases with
-amyloidosis. Total apoE is elevated with increased age in
APOE-3/4 participants but does not further increase with
-amyloidosis. Furthermore, a decrease in gene dose-normal-
ized apoE4 is seen with increasing APOE-4 genotypes most
distinctly in the-amyloid-positive condition. It is notable that,
in comparison with recent work quantitating apoE isoform
amounts in the CNS by LC-MS with synthetic peptide stan-
dards (25), we observed increases in CSF apoE3 in amyloidosis
and, in contrast, decreased CSF apoE4 in amyloidosis. The lat-
ter of which was not apparent in the study normalized with
synthetic peptide standards. This differential response of apoE3
and apoE4 amounts in response to amyloidosis may reflect a
part of themechanism that underlies AD risk. However, a time-
line for these changes relative to amyloid aggregation that is
properly controlled for the age-related increase in apoE
remains to be elucidated. Whether or not APOE-4/4 partici-
pants would be expected to demonstrate an age-related
increase in apoE in the absence of -amyloid cannot be deter-
mined from the current dataset due to the lack of older -am-
yloid-negative APOE-4 homozygous participants. Again,
obtaining CSF from APOE-4/4 individuals who are cogni-
tively robust in later life, particularly if they can be demon-
strated to have low levels of A accumulation, would greatly
enhance the interpretation of the stated observations.
In post-mortem brain tissue samples, cases with a modest
level of ADNC, apoE amount was increased (50%), approxi-
mately the same order of magnitude as observed in CSF. Nota-
bly, the age effect observed in CSF may also contribute to this
FIGURE 5. ApoE isoform amounts are equal in young healthy CSF, but amyloidosis is associated with decreased apoE with increasing APOE-4 copy
number.Adecrease in apoE3, apoE4, and apoE total amountwas associatedwithAPOE-4 carrier status such thatAPOE-3/3APOE-3/4APOE-4/4 (C).
This decrease was not observed in YNC participants (A),-amyloid-negative older participants (B), or plasma (E), although a decrease in plasma total apoEwas
significant (p 0.05, not shown) when total apoEwasmeasured by isoform sum rather than average common peptides. A similar decrease was seen in apoE3
amount, but not significant in total apoE, in brain samples (D). Results for isoform amounts were normalized for gene dose for comparison across genotypes
(see statistical methods). Error bars, 95% CI; *, p 0.05; **, p 0.01.
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TABLE 3
Pathology quantitation of frontal cortex adjacent brain tissue
Values are reported asmean (95% confidence intervals) except forAll brain, which is reported asmean (range). AF indicates area fraction ofA plaques/phosphorylatedTau
in frontal neocortex (range: 0 to 1; 1 is 100% of cortex); GL indicates gray level, mean luminance of frontal neocortex (range: 0 to 256; 0 is most intense staining). Thal A
stage indicates global A deposition staging protocol (range: 0, 1 to 5; 5 is most severe); Braak NFT stage indicates global NFT staging protocol (range: 0, 1 to 6; 6 is most
severe). CERAD NP stage indicates neuritic plaque deposition staging (range: 0, 1 to 3; 3 is most severe).
ApoE genotype
A
(10D5)-AF pTau (PHF1)-AF
Astrocytosis
(GFAP)-GL
Thal A
stage
Braak NFT
stage
CERAD
NP stage Brain weight
g
All brain 0.0399 (0.0000–0.1870) 0.0019 (0.0000–0.0405) 147.8 (124–168) 2.3 (0–5) 2.6 (1–6) 1.1 (0–4) 1208.0 (960–1450)
APOE-3/3 n 31 0.0275 (0.0136–0.0414) 0.0018 (0.0013–0.0380) 148.9 (144.2–153.7) 2.0 (1.4–2.6) 2.6 (2.1–3.1) 1.2 (0.6–1.7) 1212.1 (1164–1260)
APOE-3/4 n 10 0.0736 (0.0267–0.1204) 0.0041 (0.0050–0.0133) 146.2 (139.1–153.3) 2.8 (1.9–3.7) 3.1 (2.2–4.0) 1.0 (0.3–1.8) 1226.0 (1157–1295)
FIGURE 6. Age-dependent increase in apoE for APOE-3/3 participants. Comparing dose-normalized isoforms and total apoE within genotypes, a trend
emerged for increasing apoE amountswhere YNC-amyloid-amyloid. For theAPOE-3/3 genotype, an increased range of apoE levels was evident
with aging, with -amyloid individuals falling typically into the upper half of the range. ANOVA demonstrated a significant difference in CSF apoE3 amount
(F(2,51) 4.3, p 0.019), as well as total apoE (F(2,51) 5.9, p 0.0049). Post hoc comparisons showed that only the difference between YNC and amyloid
groups reached statistical significance (p 0.014 for apoE3 amount and p 0.0034 for total apoE). A trend toward increase in apoE3 amountwith amyloidosis
in the older APOE-3/3 cohort did not reach significance (p 0.20 for apoE3 amount and p 0.20 for total apoE). Between-group differences only reached
significance for APOE-3/4 participants in apoE4 isoform amount, again between young and -amyloid groups. ANOVA showed increased apoE4 amount
(F(2,39)4.2,p0.023),withpost hoc significancebetweenYNCandamyloidgroups (p0.021) anda trend for increasebetweenYNCs andamyloid (p
0.066). However, the trend toward higher apoE levels with -amyloid presence was not observed in the older APOE-3/4 cohort; no difference was observed
in apoE4 amount with amyloidosis (p 0.99 for apoE3 amount, p 0.99 for apoE4 amount, and p 0.99 for total apoE). APOE-4/4 YNC and -amyloid
participants did not demonstrate a difference in APOE levels by Student’s t test (p 0.99 for apoE3 amount, p 0.99 for apoE4 amount, and p 0.99 for total
apoE), although no older -amyloid-negative participants with this genotype were available for comparison.
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difference, as the post-mortem cases were older on average
than the older cohort of CSF study participants. Also similarly
to CSF, in APOE-3/4 heterozygous cases, brain exhibits a
slightly increased apoE4/apoE3 ratio (30%). Thus, where
ADNC is modest, CSF absolute quantitation of apoE isoform
amounts provides a good readout of brain tissue apoE levels,
with the relevant caveat that post-mortem brain tissue may be
affected by additional factors such as agonal state and post-
mortem interval.When comparedwith adjacent or globalmea-
sures of pathology, no relationships with apoE levels were
observed except for a positive correlation with a marker of
astrocytes (GFAP). GFAP hasmany roles in astrocyte behavior,
including motility, proliferation, maintaining the blood-brain
barrier, and injury response, and it is commonly used as a
marker of astrocytosis in neurodegenerative diseases (46).
Because CNS apoE is primarily astrocytic in origin (47), a rela-
tionship between astrocyte prevalence and apoE amount is not
surprising.
Furthermore, a robust imbalance in apoE isoform distribu-
tion in theAPOE-3/4 heterozygote participants was observed
in this work. This imbalance was reversed between the periph-
ery (apoE3  apoE4) and the CNS (apoE4  apoE3). Previous
studies have noted a reduced apoE4mole fraction in the periph-
ery (27, 41, 48–50). This imbalance has traditionally been
attributed to a difference in the distribution of each isoform
among the different sets of lipoprotein classes (48) that results
in an enhanced clearance of apoE4-containing lipoprotein par-
ticles (49). Specifically, it is believed that peripheral apoE4
FIGURE 7. CSF apoE amount, but not plasma apoE amount, is correlated to CSF-amyloid amount. Although no correlation was observed between CSF
apoE amount and A42/A40 ratio, apoE and isoform amounts were positively correlated with A40 and A42 absolute amounts (left panel). All correlations
werehighly significant (p0.0001) except apoE4amount for amyloid-negative carriers,where the relationshipwithA40 reached significance (p0.022) and
A42 did not (p 0.58). Although the relationship between A40 and apoE is highly similar between -amyloid and -amyloid groups, the slopes of the
correlations differ by group for A42 such that apoE amount rises more with increasing A42 among -amyloid participants than among -amyloid
participants. Plasma apoE amount was not significantly correlated with CSF A42/A40 ratio, A40 amount, or A42 amount (right panel). Panel tinting
demarcates categorically -amyloidwhere A42/A40 0.12.
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binds preferentially to larger lower density lipoproteins,
whereas peripheral apoE3 prefers the smaller cholesterol-rich
lipoproteins. The resulting increase in apoE toparticle ratio in the
lower density apoE4-containing particles results in a more rapid
uptake of these lipoprotein particles by effectively enhancing their
affinity for the cognate receptor (50). In the CNS (both brain and
CSF), however, a reversal of this imbalance was observed by this
study. Although this finding was also reported in previous work
(27), it is in stark contrast to another study that reported a reduced
apoE4 mole fraction in the CNS comparable with the imbalance
observed in the periphery (51). Together, these observations sug-
gest differentmechanisms of clearance for apoE-containing parti-
cles in the CNS than the periphery.
Finally, this study suggests that CSF apoE levels, but not
plasma apoE levels, correlate with A in CSF. The association
between apoE andA is well documented, and several potential
mechanisms for this association have beenhypothesized (6, 52).
Some studies have observed that apoE receptors play key roles
in A production. Other studies have pointed to an isoform-
dependent enhancement of A aggregation or impairment of
A clearance. Independent of the mechanism for this correla-
tion, the current findings also support the hypothesis that cen-
tral and peripheral apoE are separate pools and are subjected to
different metabolism. However, the observed negative correla-
tion between CSF and plasma apoE4/apoE3 ratios leaves open
the possibility of a shared regulatory mechanism with opposite
physiologic effects in each respective compartment. These
results, along with the functional understanding of apoE traf-
ficking in the CNS (where astrocytes and microglia package
lipids for local neuronal use) versus periphery (where lipopro-
tein particles are released from the liver to the blood for rela-
tively long-distance lipid transport), indicate that using plasma
apoE as a biomarker readout of CNS apoE amounts is unlikely
to be a useful strategy. Furthermore, the divergent ratios
observed between sample types reduce the likelihood that these
differences are due to inherent bias in the assay.
Taken together, the results from this study highlight the
importance of focusing on CNS-derived studies when evaluat-
ing an apoE isoform-dependent risk for amyloidosis and AD.
Furthermore, they suggest that assessment of this risk should
properly control for the possible confounding factors of
advanced age and amyloid burden. Further clarity into isoform-
dependent mechanisms holds the potential for improved ther-
apeutics for both the prevention and treatment of AD.
Experimental Procedures
CSF, Brain, and Plasma—Human studies took place at the
Washington University School of Medicine in St. Louis and
were approved by the Washington University Human Studies
Committee and the General Clinical Research Center Advisory
Committee. All participants gave informed written consent.
Human CSF was collected via lumbar catheter from 20
healthy young cognitively normal control (YNC: 22–60 years,
average 34.5 10.3 years, 8 female, 12 male) volunteers with a
familial history (parent or grandparent) of AD. Additionally, 83
older participants (40 female, 43 male) with mild AD dementia
(clinical dementia rating; CDR 0.5–1) and age-matched con-
trols were recruited in Ametabolism studies (53). Amyloido-
sis in this cohort was determined by Positron Emission To-
mography imaging with [11C]Pittsburgh compound B (PiB)
performed within 3 years of study date, where an MCBP score
higher than 0.18 was considered -amyloid (54–56). For par-
ticipants without PiB imaging, LC/MSmeasurement of CSFA
isoforms, specifically a concentration ratio of A42/A40
lower than 0.12, was used to identify -amyloid individuals
(54, 55). These criteria resulted in 40 older -amyloid-negative
(62–85 years, average 71.8 5.9 years) and 43 -amyloid-pos-
itive individuals (62–85 years, average 74.8 6.7 years). APOE
genotypewas determined by PCRby theGenetics Core in of the
Washington University Knight Alzheimer Disease Research
Center, and genotype was confirmed versus prototype by MS
isoform-specific peptide detection for all cases.
Humanplasmawas retrieved frombloodcollectedat the timeof
initial lumbar puncture in CSF studies and stored at80 °C until
use. Plasma from a subset of the older cohort of participants (n
37; 23 females and 14males) was analyzed for this study.
Brain tissue samples (middle frontal gyrus) from 41 cases of
cognitively normal (CDR  0 at death) participants were
obtained from theKnight Alzheimer’s Disease ResearchCenter
Neuropathology Core at Washington University. All brains
were assessed using the neuropathologic criteria of the Consor-
tium to Establish a Registry for Alzheimer’s Disease (CERAD)
and the NIA-Reagan Institute criteria for the neuropathologic
diagnosis of AD (35, 57). The average age at death was 86.1
years (range 64.8–107.9 years). The post-mortem interval
ranged from 2.3 to 24 h with a mean of 11.9 h. Age was not
found to covary with apoE genotype in CSF, brain, or plasma
studies, although age at death was significantly higher than older-
cohort age at CSF collection by Student’s t test (t(133)  9.3,
p  0.0001). ApoE genotype and age ranges included brain,
plasma, and CSF cases and are listed in Table 4.
Immunohistochemistry—All cases were assessed neuro-
pathologically using an established protocol (58). Briefly, 6-m
sections were stained with hematoxylin and eosin (H&E) and
cresyl violet. Immunohistochemistry was performed on depar-
affinized and rehydrated sections. For -amyloid immunohis-
tochemistry, sections were pretreatedwith formic acid (98%) to
enhance antigen retrieval. Sections were incubated with the
following primary antibodies: anti-GFAP (1:1000; DAKO,
Carpinteria, CA), mouse monoclonal anti--amyloid 10D5
(1:100,000; Lilly), and mouse monoclonal PHF-1 (1:500; a gift
from Dr. Peter Davies, Albert Einstein College of Medicine,
TABLE 4
Number of participants are by APOE genotype
Numbers and mean age (standard deviation) of CSF, plasma, and brain samples are
presented by experimental group and APOE genotype. Amyloid status was not
available for YNC participants.
Participants APOE-3/3 APOE-3/4 APOE-4/4 Total
YNC CSF 10 7 2 19
36.0 (11.3) 31.4 (10.78) 38.4 (5.85) 34.6 (10.60)
Amyloid CSF 11 28 4 43
75.3 (7.57) 75.2 (6.44) 70.6 (6.44) 74.8 (6.72)
Amyloid CSF 33 7 0 40
72.3 (6.25) 69.2 (2.54) 71.8 (5.93)
Plasma 15 18 4 37
73.5 (6.23) 73.5 (6.92) 70.6 (6.44) 73.1 (6.46)
Brain 31 10 0 41
85.9 (9.55) 84.1 (10.42) 85.5 (9.67)
Total 100 70 10 180
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New York). Species-specific biotinylated secondary antibodies
were applied followed by avidin-horseradish peroxidase, and
the chromogenic substrate diaminobenzidine tetrahydrochlo-
ride (VectorLaboratories,Burlingame,CA)wasused fordetection
of horseradish peroxidase. To ensure even staining between sec-
tions, all sections were stained as a batch. Sections were counter-
stained with hematoxylin. Additional sections were set aside for
quantitative densitometry and were not counterstained.
Estimation of-Amyloid Plaque Burden—Stereologic counts
of-amyloid plaques were undertaken in sections of the frontal
lobe (Brodmann’s area 9) using the “area fraction fractionator”
stereologic probe as implemented by the Stereo Investigator
software package (MicroBrightField, Williston, VT) and a
Nikon E800 microscope with motorized stage in three dimen-
sions. Briefly, a two-dimensional counting probe (x and y
dimensions of 50	 50m)was applied to a systematic random
sample of sites to include both the gyral crest and sulcal depth.
The outline of the area of interest was outlined using a 	4
objective, and the -amyloid plaque burden was determined
using a	20 lens.
Quantitative Immunohistochemistry of Diaminobenzidine
Tetrahydrochloride-stained Sections—As we used several anti-
bodies with optically continuous staining characteristics (vari-
able grayscale intensities) and heterogeneous morphologic fea-
tures, we employed computerized quantitative densitometric
techniques as described previously (59). Quantitation of immu-
noreactive lesions on non-counterstained sections was under-
taken by a single observer and performed as reported previously
(59). Briefly, digital images were captured using aNikon Eclipse
800 light microscope coupled to a XC30 digital camera (Olym-
pus Imaging America, Center Valley, PA). All sections immu-
nostained with one antibody were analyzed during a single ses-
sion to minimize changes due to illumination, lamp intensity,
or camera setting.
From each region of interest digital images representing
three non-overlapping fields (0.09 mm2) were captured. After
each field was captured, the stage wasmovedmanually to a new
field using fiducial landmarks, as determined by differential
interference contrast microscopy, to ensure non-redundant
evaluation. Total immunoreactivity was estimated for each
image by using the Set Threshold Function in the AnalySIS
imaging software package (Olympus Soft Imaging Solutions,
Lakewood, CO). Light intensity thresholds were selected to
maximize the signal-to-noise ratio and were applied uniformly
to all digital images. The Phase Analysis function reported the
percentage of the entire field that was included within the
threshold. This value is equivalent to the total percentage of
immunoreactivity present per field.
Isolation of ApoE and Tryptic Digestion—ApoE purification
and sample preparation are shown in Fig. 8A. ApoEwas isolated
from 0.1 ml of CSF, 0.35 ml of pooled E3* and E4* astrocyte
media internal standard (described below), and 0.55 ml of PBS
and processed as described previously (32). In brief, samples
were incubated with PHM-LipoSorb (1:20 by volume, 18 h at
4 °C). The PHM-LipoSorb was prepared according to the man-
ufacturer’s instructions (1 g/50 ml of PBS). Adsorbed apoE was
denatured and reduced in 40% trifluoroethanol, 100mM trieth-
ylammonium bicarbonate, 5 mM dithiothreitol (DTT; 30 min,
FIGURE 8.ApoE samplepreparationandpeptideproduction for comparingapoE3andapoE4amounts.A, apoE sample preparation. Similarmolar amounts of
target and molar-equilibrated ISTD apoE, in the form of physiologic lipoprotein particles, are combined in each sample and undergo purification and processing
simultaneously. In contrast, previous methods introduce synthetic peptide standards at the end of the sample preparation process and immediately prior to MS
analysis, not accounting for isoform bias that may affect the target apoE during immunoprecipitation, endoprotease digestion, or sample preparation. B, apoE3
sequence and tryptic peptides. Peptides selected for quantitation are highlighted in boxes, except apoE4 peptide. ApoE4 sequence substitutes arginine (R) at amino
acid residue 112, resulting in isoform-specific tryptic peptide LGADMEDVR. Other peptides are common between apoE3 and apoE4 isoforms. C, LC/SRM mass
spectrometry. Heavy arginine-labeled peptides (dotted lines) are eluted at the same retention time as unlabeled peptides (solid lines). All target peptides can be
detected simultaneously in a sample, as demonstrated herewith traces fromAPOE-3/4 subject CSF ith heavy arginine-labeled ISTD added.
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37 °C). Samples were alkylated with 20 mM iodoacetamide (30
min at room temperature in the dark) and quenched with an
additional 5 mM DTT (15 min at room temperature). Samples
were diluted to 10% trifluoroethanol with 100 mM triethylam-
monium bicarbonate and then digested with trypsin (1.5 g,
18 h, 37 °C; Sigma). Before analysis, samples were desalted
using TopTip C-18  carbon following the manufacturer’s
instructions (Glygen, Columbia, MD). After centrifugal evapo-
ration (45 min at 37 °C), samples were resuspended in 30 l of
5% acetonitrile, 0.1% formic acid. Brain apoE was prepared as
described for CSF with the following modifications: apoE was
isolated from samples containing 0.1 ml of 150 mg of tissue/ml
of lysis buffer (containing 150mM sodiumchloride, 50mMTris-
hydrochloride, 1% Triton X-100, and protease inhibitor, at pH
7.6) by immunoprecipitation with 5.5 mg/g Sepharose bead-
conjugatedWUE4 antibody, a monoclonal total apoE antibody
(60). Prior to digest, apoE was eluted from beads with 100%
formic acid and evaporated, and the pellet was washed with
methanol. Plasma apoE was prepared as described for brain with
the following exceptions: samples contained 0.02 ml of plasma,
with internal standard and excess PBS to a 1-ml final volume.
ELISAof pre- and post-purification apoEdemonstrated pulldown
efficacies of99% for CSF by LipoSorb (5.7% coefficient of varia-
tions across three replicates) and95% for brain byWUE4 (19.8%
coefficient of variations across three replicates).
Trypsin digestion produced apoE isoform-specific peptides
(inclusive of residue 112) LGADMEDVcGR (“c” indicates car-
boxamidomethyl cysteine residue methionine 57) from
apoE3 and LGADMEDVR from apoE4, as well as four selected
peptides distributed across the apoE sequence produced in
common by both isoforms (WELALGR, LAVYQAGAR,
LGPLVEQGR, and AATVGSLAGQPLQER; Fig. 8B). Samples
were then analyzed on a Thermo Scientific TSQ Vantage mass
spectrometer for selected reaction monitoring (SRM) analysis.
Production of Standards—ApoE3 and apoE4 isoform internal
standardswere obtained from themedia of immortalized astro-
cytes derived from knock-in mice expressing human APOE-3
or APOE-4 (33). Astrocyte cultures were maintained in L-[U-
13C6,15N4]arginine-enriched serum-free media to produce
heavy arginine-labeled apoE media (E3* and E4* media). Label
incorporation in apoE was 97% or higher. Unlabeled culture
media were produced from the same cell lines (E3 and E4
media; Fig. 1A). Heavy arginine media samples were cross-
titrated with unlabeled media internal standards to establish
the ratio at which a common peptide signal indicated an equiv-
alent concentration between isoforms (Fig. 1, B and C). Multi-
ple common peptides were assessed to avoid potential biases in
detection between peptides. Each peptide provides a separate
and independent assay supporting accurate andunbiased quan-
titation. This molar equivalent ratio of heavy arginine media
was included in each sample as an internal standard.
An external standard curve was derived from separately
pooled APOE-3/3 and APOE-4/4 CSF. These apoE3 and
apoE4 CSF stocks were cross-equilibrated using the molar
equivalent E3*/E4* media internal standard described above,
and dilution curves of the apoE3/apoE4 molar-equilibrated
CSF plus E3*/E4* media internal standard were used for nor-
malization of peptide quantitation fromCSF andbrain samples.
Nano-LC Tandem MS and Quantitation—ApoE isoform-
specific and common peptides were separated using reverse
phase by a Waters nano-ACQUITY UPLC flowing at 500
nl/min through a nano-ACQUITY BEH 130 C18, 1.7-m col-
umn (100 m	 100 mm). Peptides were loaded at 4% solution
B, followed by a three-stage gradient increasing to 12% B (over
3min), to 35%B (7min), and then to 95%B (3min). The column
was then washed for 2 min at 95% B and re-equilibrated for 2
min at 4%B (solutionA 0.1% formic acid, 2%DMSO inwater,
and solution B 0.1% formic acid, 2% DMSO in acetonitrile).
Heavy arginine-labeled and -unlabeled peptides were
detected by a TSQVantagemass spectrometer (Thermo Scien-
tific, San Jose, CA) operating in SRM mode equipped with a
nanospray ionization source (Phoenix S&T,Chester, PA).Opti-
mized conditions were determined to be at a capillary temper-
ature of 275 °Cwith a spray voltage of 1200V and a collision gas
pressure in Q2 of 2.0 mtorr. Peaks were detected and quanti-
tated using Xcalibur 2.2 in batch processing mode and then
reviewed and edited using Quan Browser (Thermo Scientific,
San Jose, CA). Precursor and product ions for each monitored
SRM transition are listed in Table 2 along with the associated
instrument-dependent collision energies. Spectra with product
ions for key apoE peptides used in the current analysis have
been previously published (32). The SRM method monitored
the doubly charged species of each peptide. All peptides were
detectedwith abundant signal in a single LC/SRMrun (Fig. 8C).
The targeted isoform-specific peptides were consistent with
the respective genotype of each individual.
ELISA—For human plasma (apoE3  apoE4) ELISA, plates
were coated with HJ15.6 (mouse monoclonal antibody gener-
ated in-house) at a concentration of 10 g/ml in carbonate
coating buffer at 4 °C overnight. After blocking with 2% BSA in
PBS for 1 h at 37 °C, the samples were loaded on the plates and
incubated overnight at 4 °C. Then the plates were incubated in
150 ng/ml HJ15.4-biotin (mouse monoclonal antibody gener-
ated in-house) for 1.5 h at 37 °C. Followed by an incubation in
1:10,000 streptavidin poly-HRP40 conjugate (Fitzgerald) for
1.5 h at room temperature, the plates were developed using
Super Slow ELISA 3,3
,5,5
-tetramethylbenzidine (Sigma) and
read on a Bio-Tek Synergy 2 plate reader at 650 nm. Recombi-
nant apoE4 (Leinco) was used as the standard for human
plasma apoE ELISA (61).
Efficiency of apoE purification comparing pre- and post-af-
finity-purified CSF (by PHM-LipoSorb, 99% recovery) and
brain (by WUE4; 96% recovery) was assessed by sandwich
ELISAusingmousemonoclonal antibodyHJ6.2 for capture and
biotinylated HJ6.1 for detection. Both antibodies were gener-
ated in-house using astrocyte-derived mouse apoE as the anti-
gen (39, 62). Recombinant human apoE3 (Leinco, St. Louis,
MO) was used as a standard.
Statistical Analysis—ANOVA with Tukey’s or linear trend
tests post hoc and Student’s t tests were carried out using
GraphPad Prism software, version 6.05 (GraphPad Software, La
Jolla, CA). Pearson’s R correlationwas calculated usingTableau
Desktop Professional Edition, version 8.3 (Tableau Software
Inc., Seattle, WA).Where apoE isoformmeasurements and com-
parisons weremade across genotypes (between heterozygous and
homozygouscarriersofAPOE-3orAPOE-4), genedosenormal-
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ization consisted of doubling the estimated isoform amount in
heterozygote carriers. Isoformmeasures for homozygous partici-
pants and total apoE for all genotypes were not adjusted.
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